Rani Therapeutics Holdings, Inc.
No SEC Form 4 filings for $RANI in the last 30 days.
See all $RANI insider activity →H.C. Wainwright reiterated a Buy rating and $11.00 price target for Rani Therapeutics (RANI) after its RaniPill platform was accepted into the FDA's Emerging Technology Program. The company reported Q2 EPS of $(0.04), beating estimates, and has $53.4M in cash. RANI also announced positive Phase 1 data for RT-114 and a partnership with PegBio for obesity treatments.
Rani Therapeutics (RANI) announced its RaniPill® Capsule™ platform was accepted into the FDA's Emerging Technology Program. This program supports innovative pharmaceutical technologies and provides early engagement with the FDA. The company aims to use this opportunity to advance its oral biologic delivery technology and automate manufacturing. Rani has partnerships with Chugai, ProGen, and PegBio for rare disease, immunology, and obesity treatments.
Rani Therapeutics (RANI) reported Q2 2026 results, with net loss narrowing to $8.4M from $11.2M YoY. Contract revenue was $1.7M, up from $0 last year. R&D expenses decreased to $5.0M, while G&A expenses rose to $5.5M. Cash reserves totaled $53.4M. The company expects to fund operations through 2027. RT-114, a GLP-1/GLP-2 dual agonist, showed positive initial data, with further results expected by year-end. RANI stock closed at $0.84, down 5.57%.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning RANI (Rani Therapeutics Holdings, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent RANI coverage spans technology, regulation and earnings.
The FDA program acceptance reduces regulatory uncertainty and supports a higher valuation.
Positive regulatory engagement expected to boost investor confidence and support future product development.
Quarterly earnings beat expectations on reduced loss and new contract revenue; cash runway extended.
Clinical readout plus a $20M registered direct offering and CFO/board changes create near-term catalysts for RANI’s risk and funding outlook.
Positive early PK/bioavailability read-through for RT-114 supports the RaniPill obesity pipeline, but near-term catalysts hinge on expansion and repeat-dose plans.
AlphAI scores every news story that mentions RANI with an AI model for sentiment and relevance, and aggregates insider trades from Rani Therapeutics Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright reiterated a Buy rating and $11.00 price target for Rani Therapeutics (RANI) after its RaniPill platform was accepted into the FDA's Emerging Technology Program. The company reported Q2 EPS of $(0.04), beating estimates, and has $53.4M in cash. RANI also announced positive Phase 1 data for RT-114 and a partnership with PegBio for obesity treatments.
2 min readRani Therapeutics (RANI) announced its RaniPill® Capsule™ platform was accepted into the FDA's Emerging Technology Program. This program supports innovative pharmaceutical technologies and provides early engagement with the FDA. The company aims to use this opportunity to advance its oral biologic delivery technology and automate manufacturing. Rani has partnerships with Chugai, ProGen, and PegBio for rare disease, immunology, and obesity treatments.
2 min readRani Therapeutics (RANI) reported Q2 2026 results, with net loss narrowing to $8.4M from $11.2M YoY. Contract revenue was $1.7M, up from $0 last year. R&D expenses decreased to $5.0M, while G&A expenses rose to $5.5M. Cash reserves totaled $53.4M. The company expects to fund operations through 2027. RT-114, a GLP-1/GLP-2 dual agonist, showed positive initial data, with further results expected by year-end. RANI stock closed at $0.84, down 5.57%.
2 min readRani Therapeutics Holdings, Inc. (RANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update ~ Continues to advance RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort; additional data expected by end of 2026~ ~ Announced positive initial Phase 1a da
6 min readRani Therapeutics (Nasdaq: RANI) reported Q2 2026 results and updates on RT-114. In Phase 1a, oral RT-114 via the RaniPill Capsule showed bioavailability >150% vs matched subcutaneous PG-102, with similar half-life and no serious adverse events. Rani dosed an expansion cohort, plans Phase 1b repeat-dose obesity study by end-2026, and completed a $20m registered direct offering. Cash was $53.4m at June 30, 2026; Q2 contract revenue was $1.7m and net loss $8.4m.
6 min readRani Therapeutics Holdings, Inc. (RANI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Director Appointment On August 1, 2026, Michelle Gilson was appointed to the Board, effective immediately, until the earlier
2 min readIMRAN MIR A purchased 36,000 shares of Rani Therapeutics Holdings, Inc. (RANI) at $0.69 on 2026-07-21.
1 min readImran Talat (Chief Executive Officer) purchased 35,000 shares of Rani Therapeutics Holdings, Inc. (RANI) at $0.72 on 2026-07-17.
2 min readRani Therapeutics (RANI) reported Phase 1a results for RT-114, an oral RaniPill capsule delivering PG-102, a GLP-1/GLP-2 dual agonist from ProGen. In 30 healthy volunteers, oral RT-114 produced >150% systemic exposure vs 12 mg subcutaneous, with similar half-life (5.6 vs 5.3 days) and no serious adverse events. Phase 1b is underway; data expected in 2027.
4 min readRani Therapeutics (Nasdaq: RANI) said it entered an R&D collaboration with PegBio to use RaniPill to develop oral formulations of multiple PegBio obesity and metabolic disease candidates. The work will focus on preclinical development with the aim of moving selected molecules into clinical testing. Rani also cited its Phase 1 RT-114 GLP-1/GLP-2 dual agonist and other preclinical obesity candidates.
4 min read
